|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The basics of epithelial-mesenchymal transition显示文摘 | Kalluri Raghu Weinberg Robert A | 2009 | Journal of Clinical Investigation2009，，6： | 17 |
| 2 | An evolving function of DNA-containing exosomes in chemotherapy-induced immune response显示文摘 | Paul Kurywchak Raghu Kalluri | 2017 | Cell Research2017，27，6： | 6 |
| 3 | Current state of renal transplant immunosuppression:Present and future显示文摘For kidney transplant recipients, immunosuppression commonly consists of combination treatment with a calcineurin inhibitor, an antiproliferative agent and a corticosteroid. Many medical centers use a sequential immunosuppression regimen where an induction agent, either an anti-thymocyte globulin or interleukin-2 receptor antibody, is given at the time of transplantation to prevent early acute rejection which is then followed by a triple immunosuppressive maintenance regimen. Very low rejection rates have been achieved at many transplant centers using combinations of these agents in a variety of protocols. Yet, a large number of recipients suffer chronic allograft injury and adverse events associated with drug therapy. Regimens designed to limit or eliminate calcineurin inhibitors and/or corticosteroid use are actively being pursued. An ideal immunosuppressive regimen limits toxicity and prolongs the functional life of the graft. This article contains a critical analysis of clinical data on currently available immuno-suppressive strategies and an overview of therapeutic moieties in development. | Hari Varun Kalluri Karen L Hardinger | 2012 | World Journal of Transplantation2012，2，4： | 5 |
| 4 | 显示文摘 | Kalluri R | 2003 | Nat Rev Cancer2003，3，6： | 1 |
| 5 | Tumstatin,the NCI domain of a3 chain of type Ⅳ collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth 显示文摘 | Hamano Y Kalluri R | 2005 | Biochem Biophys Res Commun2005，333，2： | 1 |
| 6 | The basics of epithelial- mesenchymal transition 显示文摘 | Kalluri R Weinberg R A | 2009 | J Clin Invest2009，119，8： | 1 |
| 7 | EMT:when epithelial cells decide to become mesenchymal-like cells显示文摘 | Kalluri R | 2009 | J Clin Invest2009，119，6： | 1 |
| 8 | The epithelial mesenchymaltransition:new insights in sighaling,development and disease显示文摘 | Lee JM Dedhar S Kalluri R5 | 2006 | J Cell Biol2006，172，7： | 1 |
| 9 | Fibroblasts in cancer 显示文摘 | Kalluri R Zeisberg M | 2006 | Nat Rev Cancer2006，6，5： | 1 |
| 10 | The basics of epithelial-mesenchymaltransition显示文摘 | Kalluri R Weinberg RA | 2009 | J Clin Invest2009，119，6： | 1 |
| 11 | The role of epithelial-to-mesenchymal transition in renal fibrosis显示文摘 | Zeisberg M Kalluri R | | 0，，03： | 1 |
| 12 | Distortion-product source unmixing: A test of the two-mechanism model for DPOAE generation 显示文摘 | Kalluri R Shera C A | 2001 | JAcoust Soc Am2001，109，： | 1 |
| 13 | Cancer without disease显示文摘 | Folkman J Kalluri R | 2004 | Nature2004，427，6977： | 1 |
| 14 | Tumstatin, the NC1 domain of alpha3 chain of type Ⅳ collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth 显示文摘 | Hamano Y Kalluri R | 2005 | Biochem Biophys Res Commun2005，333，2： | 1 |
| 15 | Epithelial-mesenchymal transition and its implications for fibrosis显示文摘 | Kalluri R Neilson EG | 2003 | J Clin Ivest2003，112，12： | 1 |
| 16 | Early role of Fspl in epithelialmesenchymal transformation 显示文摘 | Okada H Danoff TM Kalluri R | 1997 | Am J Physiol1997，273，42： | 1 |
| 17 | Genome-wide analysis of Aux/IAA and ARF gene families in Populus trichocarpa显示文摘 | Kalluri U C Difazio S P Brunner A M | 2007 | BMC Plant Biology2007，7，： | 1 |
| 18 | The origin of fibroblasts and mechanism of cardiac fibrosis 显示文摘 | Krenning G Zeisberg E M Kalluri R | 2010 | J Cell Physio12010，225，3： | 1 |
| 19 | Ion channels in mammalian vestibular afferents may set regularity of fir-ing显示文摘 | EATOCK RA XUE J KALLURI R | 2008 | J Exp Biol2008，211，： | 1 |
| 20 | Basement membranes: structure, assembly and role in tumour angiogenesis 显示文摘 | Kalluri R | 2003 | Nat Rev Cancer2003，3，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员